Morgan Stanley adjusted its 2011 and 2013 EPS estimates for Lexicon Pharmaceuticals (NASDAQ:LXRX) and maintained its equal-weight rating and $2 price target.
The bank sees a 2011 loss of $0.32 per share, narrower than its previous estimate for a loss of $0.34 per share, and a 2013 loss of $0.29 per share, narrower than its previous estimate for a loss of $0.30 per share.
Lexicon Pharmaceuticals has a potential upside of 129% based on a current price of $1.31 and an average consensus analyst price target of $3.
Link to this comment:
All Comments (0)